Giltuss

Quick links to important sections

Giltuss

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Giltuss

Quick Facts

Property Description
Active Ingredients Dextromethorphan HBr, Guaifenesin, Phenylephrine HCl
Form Oral Solution, Syrup, or Tablet
Pharmacological Class Upper Respiratory Combination
Primary Actions Antitussive, Expectorant, Decongestant
Origin Synthetic Active Ingredients

What Kind of Medicine is Giltuss? (Definition and Classification)

Giltuss is a synthetic, multi-symptom combination drug designed for oral administration, formally classified as an Upper Respiratory Combination medication. This categorization signifies that the pharmaceutical preparation is a fixed-dose formula aimed at concurrently managing several complaints associated with respiratory irritations. The composition, which is available in dosage forms such as liquid solution and tablets, provides an integrated treatment option that differs from single-entity preparations targeting only one symptom.

Composition and Triple-Action Formula

The therapeutic basis of Giltuss relies on the presence of three distinct active ingredients: Dextromethorphan Hydrobromide, Guaifenesin, and Phenylephrine Hydrochloride. Each ingredient corresponds to a separate pharmacological action: the antitussive, the expectorant, and the nasal decongestant, respectively. This specific triad is intended for the symptomatic relief of the common cold. The inclusion of the expectorant Guaifenesin is designed to help loosen mucus and phlegm in the chest, making coughs more productive.

General Purpose and Mechanism Summary

The general purpose of this preparation is to provide comprehensive, integrated relief from three major symptoms: a persistent cough, mucus accumulation in the chest, and nasal congestion, such as may occur during a typical viral upper respiratory infection. The product's intended function is achieved by suppressing the central cough reflex, thinning viscous respiratory secretions, and promoting local vasoconstriction in the nasal lining to reduce swelling. Dextromethorphan, one of its core components, functions as a central cough suppressant. This triple-action profile is designed for symptomatic management.

Regulatory References

  1. MedlinePlus, Guaifenesin
  2. NIH, Dextromethorphan Monograph

What side effects are possible with Giltuss?

Possible Side Effects and Safety Information

The official safety profile for the active ingredients in Giltuss (Dextromethorphan HBr, Guaifenesin, and Phenylephrine HCl) is structured by classifying possible adverse reactions based on frequency and affected physiological system, according to government regulatory documentation.

Adverse Reaction Classification

Side effects are often categorized into specific System-Organ Classes (SOC) within regulatory labels. These include effects on the Nervous System (e.g., dizziness, drowsiness, sleeplessness) and the Gastrointestinal System (e.g., nausea, stomach upset, diarrhea, constipation). Effects like nervousness, irritability, and restlessness are classified under Psychiatric Disorders.

Reactions commonly reported in regulatory documents include dizziness, drowsiness, insomnia, and certain gastrointestinal upsets.

Serious Adverse Reactions and Constraints

Regulatory sources explicitly document serious adverse reactions that include significant changes in heart rhythm and dangerously high blood pressure (Cardiovascular and Vascular Disorders). Other serious events include seizures (convulsions), confusion, hallucinations, and signs of a severe allergic reaction (e.g., difficulty breathing, swelling).

Regulatory Safety Constraints mandate strict restrictions against use within 14 days of taking a Monoamine Oxidase Inhibitor (MAOI). Furthermore, the label advises caution regarding driving or operating machinery due to the potential for dizziness or drowsiness.

Population-Specific Safety Notes

The safety profile includes population-specific safety statements required by regulatory authorities. Specific warnings are listed for individuals with pre-existing conditions such as heart disease, high blood pressure, diabetes, thyroid disorder, or glaucoma. Official guidance often restricts use in children under 4 years of age and advises consultation for pregnancy or breastfeeding.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Giltuss overdose is defined by the toxicological effects of its active ingredients: Dextromethorphan (a central nervous system agent) and Phenylephrine (a sympathomimetic agent). Overdose necessitates immediate attention due to the high risk of severe complications.

Feature Documented Regulatory Statement
Documented Manifestations Clinical signs may include central nervous system (CNS) effects such as confusion, agitation, hallucinations, nystagmus, and progression to stupor or coma. Cardiovascular presentations include hypertension, tachycardia, and other cardiac arrhythmias. Respiratory distress and severe nausea/vomiting may also occur.
Severe Complications Risks documented in regulatory texts include serotonin syndrome, hypertensive crisis, and respiratory depression leading to apnea, which are potentially life-threatening. Seizures and hyperpyrexia are also noted.
Required Emergency Action Health authorities explicitly mandate that individuals must seek immediate medical attention or contact a Poison Control Center right away upon any suspicion of overdose.

Management is primarily symptomatic and supportive care. The official guidance states that no specific antidote is known for the Dextromethorphan component. Required procedures involve continuous monitoring of vital signs, Electrocardiogram (ECG), and necessary laboratory testing. Naloxone may be considered by medical professionals for the reversal of severe respiratory and CNS depression. Overdose complications may be more severe in children and the elderly.

Therapeutic Uses of Giltuss

What Giltuss Treats: Main Uses and Benefits

Giltuss is applied across domains where additional symptomatic support is needed to help address clusters of symptoms associated with acute respiratory episodes. The core therapeutic benefit is to provide supportive relief, and it may assist with maintaining functional stability during difficult episodes.

The medication is commonly used for managing conditions characterized by periods of heightened symptoms, which include the common cold, flu, and seasonal upper respiratory allergies. It is relevant for easing symptoms related to both irritative states in the respiratory tract and nasal blockage.

Therapeutic Focus Areas

This support is primarily relevant for easing symptoms related to persistent cough, chest congestion, mucus build-up, and stuffy nose. The use is applied during phases of increased distress or discomfort when symptoms may become temporarily overwhelming.

Quick Fact: Supportive Management of Cough and Congestion The product supports the patient during difficult episodes and helps address groups of symptoms that may become intense, which contributes to easing the overall symptom load.

Regulatory References

  1. NIH DailyMed overview

Eligibility and Restrictions for Use

The official regulatory profile for Giltuss establishes strict rules for population eligibility based on co-medication status, age, and pre-existing health conditions.

Category Eligibility Rule
Contraindications Use is strictly prohibited for individuals currently taking, or who have discontinued within the last 14 days, a Monoamine Oxidase Inhibitor (MAOI).
Age Eligibility Use is permitted for adults and children 12 years and over. Use in children under 12 years is conditional, and all children under 2 years require consultation with a doctor.

Conditional Use (Consult a Doctor) Prior consultation with a healthcare professional is explicitly required for individuals with specific pre-existing health conditions or circumstances, as stated in the labeling:

  • Cardiovascular/Endocrine: Patients with heart disease, high blood pressure, diabetes, or thyroid disease.
  • Pulmonary/Urological: Individuals with a persistent or chronic cough (such as from asthma or emphysema), a cough with excessive phlegm, or difficulty urinating due to an enlarged prostate gland.
  • Physiological State: Individuals who are pregnant or breast-feeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Giltuss establishes strict rules for co-administration with specific medicine classes and substances. The most significant restriction classifies Monoamine Oxidase Inhibitors (MAOIs) as contraindicated combinations due to the high risk of severe adverse reactions. This prohibition requires a mandatory separation period, stating that the product must not be used for 14 days after stopping an MAOI drug. This is a critical timing-based interaction rule based on regulatory documentation.

Pharmacokinetic interactions are officially documented for substances that inhibit the CYP2D6 enzyme system, which is responsible for metabolizing the Dextromethorphan component. These CYP2D6 inhibitors increase the systemic exposure and plasma concentrations of Dextromethorphan, which requires awareness. Furthermore, the profile details potential additive pharmacodynamic effects. Co-administration with other CNS Depressants (such as certain tranquilizers or sedatives) is restricted due to the combined risk of effects like increased drowsiness. Similar restrictions apply to Serotonergic Agents and other Sympathomimetics to mitigate the risk of serotonin syndrome or excessive stimulation. Alcohol is also specifically restricted by the regulatory documents due to its additive CNS depressant properties. The overall interaction structure is defined by these prohibitions and the recognized concentration-altering and additive effect patterns documented in regulatory sources.

Mechanism of Action

How Giltuss Works

Giltuss is formulated to exert its effect through distinct and complementary mechanistic domains, targeting central neurological pathways, respiratory fluid dynamics, and peripheral vascular tone. Its action profile is achieved by modulating multiple, underlying physiological systems.


Modulating the Central Cough Reflex

The antitussive component (Dextromethorphan) targets the medullary cough center in the brainstem. By engaging specific sigma-1 receptors, it modulates the cough threshold, initiating a cascade that reduces the central signaling responsible for generating the cough reflex. The resulting physiological effect is the dampening of reflexive output from the medullary cough center, which limits the central nervous system response.


Regulating Bronchial Secretion Properties

The expectorant component (Guaifenesin) influences the properties of mucus via the gastro-pulmonary reflex. It promotes an increase in the volume and hydration of respiratory tract secretions. This modification of the secretion structure promotes the clearance of viscous material from the respiratory tract.


Peripheral Sympathomimetic Vasoconstriction

The decongestant component (e.g., Phenylephrine) acts on the alpha1-adrenergic receptors found on blood vessels in the nasal mucosa. This receptor binding initiates a signaling sequence that causes local vasoconstriction (narrowing of blood vessels). The resulting physiological effect is the reduction of tissue swelling and fluid accumulation in the nasal passages, which results in the reduction of tissue fluid volume within the nasal mucosa.

Dosage and Administration Information

How Giltuss is Used: Official Administration Guidelines

Giltuss (Dextromethorphan HBr, Guaifenesin, and Phenylephrine HCl) is administered exclusively via the oral route, typically available as a liquid solution/syrup or in various tablet forms. The medication is strictly intended for short-term use and should be taken only as needed, according to a defined schedule, with a mandatory limit on the duration of administration.


Official Dosing and Frequency

The usage protocol is based on the specific formulation. The dosage frequency and maximum daily intake must not be exceeded, structuring the use as an intermittent therapy.

Formulation Type Typical Adult Dosing (Ages 12 and older) Frequency and Maximum
Oral Solution/Syrup 5 mL to 10 mL per dose Every 4 hours; Do not exceed 6 doses in 24 hours.
Extended-Release Tablet 1 tablet per dose Every 6 to 8 hours; Do not exceed 4 tablets in 24 hours.

Administration Requirements and Duration

For liquid preparations, a dosing cup or other calibrated device supplied with the product must be used to ensure accurate administration of the prescribed volume. Extended-release tablets are generally to be swallowed whole. The usage protocol is restricted, and the medication should not be used for more than seven consecutive days; if symptoms persist or reoccur beyond this time frame, professional guidance is required. Pediatric dosing is explicitly age-stratified, and some labels advise against use in children under 4 years of age unless directed by a healthcare provider. The administration schedule is symptom-driven, emphasizing the strict limits on dose frequency and total duration.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Clinical Research

Research has examined the components of Giltuss, which typically include an expectorant (guaifenesin) and a cough suppressant (dextromethorphan), and may include a nasal decongestant (phenylephrine). The research was designed to examine the drug's effect on specific inflammatory or reflex pathways associated with upper respiratory symptoms.


Phase 3 Trials: Symptom Management

  • Study Design: Trials involving this drug combination have been conducted, often utilizing double-blind, randomized, and placebo-controlled designs.
  • Objective: Researchers evaluated the severity and frequency of cough, chest congestion, and, where applicable, nasal congestion, in participants with symptoms related to the common cold or other respiratory tract infections.
  • Key Findings:
    • Cough Suppression: Studies assessed the potential for dextromethorphan to reduce the frequency and intensity of coughing.
    • Expectorant Effect: Research examined the capacity of guaifenesin to thin and loosen bronchial secretions.

Pharmacokinetic and Safety Data

Pharmacokinetic Profile

The combined formulation is designed for simultaneous activity. Pharmacokinetic data show that the components are absorbed from the gastrointestinal tract, with dextromethorphan metabolized by the liver, and guaifenesin excreted primarily through the kidneys. The elimination half-life of dextromethorphan can vary between individuals.

Adverse Events Profile

Studies recorded instances of common side effects, which include dizziness, nausea, vomiting, headache, and drowsiness.

  • Severe Adverse Events (SAEs): Serious Adverse Events (SAEs) were documented, including rare reports of severe allergic reactions or effects related to the misuse of the dextromethorphan component.
  • Evidence Limitations: The reported findings are specific to the study populations and conditions assessed. Further research is necessary to assess generalizability across wider patient populations and long-term use.

Frequently Asked Questions (FAQ)

Common questions about Giltuss (FAQ)


Q: Is Giltuss considered a prescription or an over-the-counter medicine?

Giltuss is formally classified in official regulatory documents as a Human OTC Drug, meaning it is available as an Over-The-Counter medication. This classification signifies that the product is intended for self-selection and use without requiring a prescription from a healthcare provider.


Q: Why is Giltuss often used by people with bronchitis?

Regulatory information indicates that Giltuss is used for the temporary relief of cough and bronchial irritation associated with conditions like the common cold or inhaled irritants. Bronchitis symptoms often involve persistent cough and irritation, which align with the product's intended uses.


Q: What is the difference between Giltuss and other cough/cold medicines?

Official product information classifies Giltuss as an Upper Respiratory Combination medication, meaning it provides a fixed dose of three specific active ingredients. This combination includes a cough suppressant, an expectorant, and a nasal decongestant, offering relief for multiple symptoms simultaneously.


Q: Does Giltuss contain an antihistamine?

The core Giltuss triple-action formula does not contain an antihistamine. However, it is important for the user to check the active ingredients list on their specific package, as some other Giltuss brand formulations may include an antihistamine like Chlorpheniramine Maleate.


Q: Are there any reported long-term side effects associated with Giltuss?

Official regulatory documents advise against using the product for more than seven consecutive days. The documented side effect information (such as dizziness and nausea) focuses on acute events during the recommended short-term use, and regulatory labels do not provide specific data on effects beyond this advised duration.


Q: Is there a non-drowsy version of Giltuss available?

Official warnings note that certain active ingredients in Giltuss formulations, particularly those with antihistamines, can cause drowsiness. The availability of a non-drowsy version depends on the specific combination of ingredients, as some formulas may contain only non-sedating components.


Q: What is the meaning of 'contraindication' when reading about Giltuss?

A contraindication is a strict rule defined in the official regulatory labeling for the medicine. It indicates a specific situation or pre-existing health condition in which the drug must not be used because the risk of harm outweighs any potential benefit.


Q: Is Giltuss habit-forming or addictive?

Official warnings focus on the risk of serious harm associated with the misuse or abuse of the Dextromethorphan component. Dependence is a known risk associated with the abuse of these types of ingredients.


Q: Is it possible for Giltuss to cause nervousness or restlessness?

Official drug labels list nervousness, restlessness, and sleeplessness as possible adverse reactions. These effects are often associated with the decongestant component, Phenylephrine, which can have stimulating effects.


Q: What should a person do if they miss a scheduled use of Giltuss?

Official administration instructions emphasize strict limits on the total daily dose and frequency of use. General guidance consistent with regulatory principles suggests avoiding double doses. If it is almost time for the next scheduled dose, the common procedure is to skip the missed dose and resume the usual timing.


Q: Is Giltuss available in different forms, such as liquid or tablet?

Official regulatory labels confirm that Giltuss is available in multiple forms. These include various preparations such as oral solutions or syrups and extended-release tablets.


Q: Can Giltuss be taken if someone is also using another decongestant?

Official regulatory warnings strictly advise against using the product when you are already taking any other oral nasal decongestant or stimulant. This prohibition is due to the potential for excessive combined effects.


Q: Is Giltuss gluten-free?

Official labels do not typically label the product as 'gluten-free.' While gluten-containing ingredients are not commonly listed among the inactive ingredients in many liquid formulations, it is necessary to check the inactive ingredient list on the specific package for certainty.


Q: Does Giltuss contain ingredients that are stimulants?

Yes. The active ingredient Phenylephrine HCl is a decongestant that is pharmacologically classified as a sympathomimetic agent. This type of ingredient acts on blood vessels and can have a stimulating effect on the body.


Q: Are there different Giltuss formulations (e.g., day vs. night)?

Regulatory labels show that Giltuss is available in multiple product lines with varied combinations of active ingredients. These variations allow for different therapeutic profiles—for example, formulas that may or may not include a sedating component often used for 'night' products.


Q: Does Giltuss affect blood sugar levels?

Regulatory documents advise caution for individuals with diabetes before use. The decongestant component (Phenylephrine) is a sympathomimetic agent, and some sympathomimetic agents are associated with potential increases in blood glucose concentrations.


Q: What are the typical ingredients found in a Giltuss product?

Official regulatory labels list both the active and inactive components. The active ingredients are typically Dextromethorphan, Guaifenesin, and Phenylephrine HCl. The inactive ingredients vary by formulation (liquid or tablet) but include substances like artificial flavors, coloring agents, and binders.


Q: Is Giltuss considered a multi-symptom relief medicine?

Yes, official drug information and labeling for many products refer to Giltuss as providing Multi-Symptom relief. This term signifies that the medicine contains a combination of ingredients to target several symptoms associated with a cold, such as cough, congestion, and mucus buildup.


Q: Does Giltuss contain pseudoephedrine or phenylephrine?

Official labels confirm that Giltuss contains Phenylephrine HCl as an active ingredient, which acts as a nasal decongestant. However, the core Giltuss formulations do not list Pseudoephedrine as an active ingredient.


Q: What is the meaning of the warning about 'excitability' in children using Giltuss?

Official warnings state that excitability may occur, especially in children. This is a potential adverse reaction listed in regulatory documents for the product. This effect is generally associated with the sympathomimetic (decongestant) or antihistamine components in combination cold medicines.


Q: Can Giltuss be taken with common pain relievers like acetaminophen or ibuprofen?

Regulatory warnings advise against combining Giltuss with other medications containing Acetaminophen to avoid accidental overdose of that ingredient. It is important that the user verifies the warnings and ingredients list on all products used concurrently.


Q: Does Giltuss interact with common herbal supplements like St. John's Wort?

Official interaction documents for some Giltuss product lines specifically warn about potential interactions with the herbal supplement St. John's wort. Users should check the detailed warning sections on the product packaging for specific interaction rules regarding supplements.


Q: Can Giltuss be used for a dry cough?

The official uses of Giltuss include the temporary relief of coughs due to minor throat and bronchial irritation. This relief is provided by the Dextromethorphan component, which acts as a cough suppressant and is indicated in regulatory documents for the treatment of nonproductive coughs (dry coughs).


Q: Is the side effect profile of Giltuss generally considered mild?

Official drug information lists both common side effects (such as dizziness and nausea) and serious adverse events (SAEs), which include effects like seizures and dangerously high blood pressure. Due to the presence of both common and serious reported events, regulatory documents do not provide a general 'mild' classification.


Q: What is the duration of treatment that Giltuss is intended for?

Official labels explicitly mandate that the product should not be used for more than 7 days. If a cough or cold symptoms persist or return after this period, it is indicated that the individual seek professional guidance.


Q: How long do the effects of Giltuss typically last?

Official regulatory labels provide strict dosing intervals for Giltuss formulations, such as dosing every 4 to 8 hours. These intervals indicate the intended duration of the pharmacological effect for each dose.


Q: Is Giltuss appropriate for children of all ages?

Regulatory documents provide explicit age-stratified guidelines and restrictions. Use in children under 2 years is conditional and that professional consultation is necessary, and specific multi-symptom formulations may be advised against for children under 6 years.

How should Giltuss be stored and disposed of?

How to Store and Dispose of Giltuss

Official regulatory guidelines strictly define the necessary conditions for storing and disposing of Giltuss, based on the approved product labeling.

Storage Conditions

Requirement Official Statement
Temperature Store at controlled room temperature (e.g., 20 C to 25 C).
Environment Must be stored away from both light and moisture.
Prohibition Do not freeze liquid forms. Do not store in the bathroom.
Safety Keep all medication out of the reach of children and pets.

Disposal Rules

Requirement Official Statement
Method Do not flush or pour down a drain unless specifically instructed.
Guidance Consult a pharmacist or local waste disposal company for proper disposal methods for expired or unused product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Giltuss found in:

A-Z Index: